The heavy selling pressure might have exhausted for Viking (VIK) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in ...

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $29.73, denoting a +0.61% change from the preceding trading day.

Viking Holdings told investors Tuesday during its Q4 earnings call that the company has sold 88% of 2025 inventory, with ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report). The ...

Since, Viking's clinical data remain strong, and the company aims to launch a phase 3 trial for the injectable version of VK2735 in the second quarter. It's also advanced an oral version, starting a ...

Viking Holdings Ltd. is banking on affluent customers to see it through this period of jitters in the travel industry.

For our Core Products, operating capacity is 12% higher for the 2025 season compared to the 2024 season. As of February 23 for our Core ...

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from ...

As of Feb. 23, the company had recorded $5.3 billion in advance bookings year-to-date for 2025, up 26% year-over-year. "These are very good trends for 2025," Viking CEO Tor Hagen said on the call. " ...

Viking Holdings Ltd (VIK) reports a significant turnaround with a $104 million net income and outlines ambitious expansion and technological advancements.

Shares surged as high as $99.41 in the following days. VK2735 is such a profound contender that an Oppenheimer research analyst upgraded the price target to $138 per share on March 26, 2024. Viking is ...